New protein may suppress breast cancer growth

September 14, 2011

Research led by Dr. Suresh Alahari, the Fred Brazda Professor of Biochemistry and Molecular Biology at LSU Health Sciences Center New Orleans and its Stanley S. Scott Cancer Center, has found that a protein discovered by his laboratory can inhibit the growth of breast cancer cells. The research will be published September 14, 2011 online in the Journal of the National Cancer Institute.

Building upon Dr. Alahari's earlier discovery of Nischarin, a novel protein that regulates breast cancer cell migration and movement, this current study examines the presence and levels of Nischarin in breast cancer tumor tissue from 300 women as well as normal breast tissue samples. The researchers also generated derivatives of human metastatic to test by manipulating the protein in a mouse model.

"We found that normal human breast tissue samples had statistically significantly higher levels of Nischarin compared with tumor tissue samples," notes Dr. Alahari, "and tumors grew significantly faster in the cells where we blocked the production of Nischarin. Tumor growth and metastasis were also reduced in the samples where we manipulated the overproduction of Nischarin. Our research shows that Nischarin can function as a of breast cancer, inhibiting breast cancer progression."

The research team also describes the regulation of Nischarin and reports the genetic mechanism by which this protein suppressed growth, information that could be used to target new treatment approaches.

Excluding skin cancer, breast cancer is the most common type of cancer among women in the United States. The National Cancer Institute estimates 230,480 new cases among American females this year, and 2,140 among men in the US, with 39,520 deaths in women and 450 deaths in men.

Risk factors include aging, weight gain, combined hormone therapy, , and consumption of one or more alcoholic beverages per day. A family history increases risk, as does never having had children or having a first child after age 30.

Mammography can often detect breast cancer at an early stage when treatment options are greatest and a cure is possible.

"Next steps include determining whether Nischarin controls some of its tumor suppressor roles through regulation of the pathways we reported in this paper," concludes Dr. Alahari, "and these studies are already underway."

The LSUHSC research team also included Dr. Robin McGoey, Associate Professor of Pathology. as well as postdoctoral fellows, Drs. Somesh Baranwal, Yanfang Wang, Rajamani Rathinam, and Lianjin Jin. Researchers from Duke University and Memorial Sloan Kettering Cancer Center also contributed.

Related Stories

Recommended for you

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.